Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Insider Sells $398,708.73 in Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) insider Natarajan Sethuraman sold 25,907 shares of the firm’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $15.39, for a total transaction of $398,708.73. Following the sale, the insider owned 216,317 shares in the company, valued at approximately $3,329,118.63. This trade represents a 10.70% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Entrada Therapeutics Stock Performance

NASDAQ TRDA opened at $16.03 on Thursday. Entrada Therapeutics, Inc. has a 52-week low of $4.93 and a 52-week high of $16.45. The company has a fifty day moving average of $12.91 and a 200-day moving average of $10.89. The company has a market capitalization of $622.30 million, a P/E ratio of -4.63 and a beta of -0.09.

Entrada Therapeutics (NASDAQ:TRDA) last released its earnings results on Thursday, February 26th. The company reported ($0.94) EPS for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.38. Entrada Therapeutics had a negative return on equity of 39.83% and a negative net margin of 565.48%.The business had revenue of $1.30 million for the quarter, compared to analysts’ expectations of $7.41 million. As a group, analysts forecast that Entrada Therapeutics, Inc. will post -4.22 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of TRDA. Allspring Global Investments Holdings LLC lifted its stake in shares of Entrada Therapeutics by 11.3% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 19,465 shares of the company’s stock valued at $246,000 after acquiring an additional 1,970 shares during the last quarter. Hsbc Holdings PLC boosted its holdings in Entrada Therapeutics by 83.1% during the 1st quarter. Hsbc Holdings PLC now owns 38,137 shares of the company’s stock valued at $472,000 after acquiring an additional 17,304 shares during the period. Invesco Ltd. grew its position in Entrada Therapeutics by 41.1% during the 4th quarter. Invesco Ltd. now owns 41,033 shares of the company’s stock worth $422,000 after acquiring an additional 11,958 shares during the last quarter. XTX Topco Ltd increased its stake in Entrada Therapeutics by 26.4% in the 4th quarter. XTX Topco Ltd now owns 117,668 shares of the company’s stock worth $1,210,000 after purchasing an additional 24,589 shares during the period. Finally, Wellington Management Group LLP increased its stake in Entrada Therapeutics by 9.5% in the 4th quarter. Wellington Management Group LLP now owns 1,044,758 shares of the company’s stock worth $10,740,000 after purchasing an additional 90,339 shares during the period. Hedge funds and other institutional investors own 86.39% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the company. Weiss Ratings reissued a “sell (d)” rating on shares of Entrada Therapeutics in a report on Friday, March 27th. Cantor Fitzgerald started coverage on Entrada Therapeutics in a research note on Wednesday, April 1st. They issued an “overweight” rating for the company. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Entrada Therapeutics in a research report on Wednesday, February 18th. Wall Street Zen downgraded shares of Entrada Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Finally, Guggenheim upgraded shares of Entrada Therapeutics to a “strong-buy” rating in a report on Wednesday, February 11th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.00.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.